Perspective Therapeutics, Inc. announced that two upcoming investigator-initiated trials (IIT) were presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023. Presentation One: Phase 1 Trial of Pb-212-VMT-alpha-NET in patients with metastatic or inoperable somatostatin receptors positive (SSTR+) tumors to investigate if this new treatment can improve management of patients nave to prior radioligand therapy. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT--NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions in the United States.

The Company has also developed a proprietary Lead-212 generator to enable isotope supply for clinical trial and commercial operations. In addition to its targeted alpha therapy programs, Perspective is the sole producer of Cesium-131 brachytherapy seeds which are commercially available in the United States for the treatment of prostate cancer and other solid tumors. words such as " may, "will," "should," "plan," "anticipate," " could,intend," target, project,estimate, "believe," "predict," "pot potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words.